Concepts (206)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aortic Valve Stenosis | 15 | 2024 | 172 | 5.270 |
Why?
|
| Heart Valve Prosthesis | 11 | 2024 | 94 | 4.740 |
Why?
|
| Transcatheter Aortic Valve Replacement | 14 | 2024 | 96 | 4.450 |
Why?
|
| Aortic Valve | 13 | 2024 | 175 | 2.680 |
Why?
|
| Coronary Vessels | 6 | 2021 | 110 | 2.630 |
Why?
|
| Bioprosthesis | 4 | 2021 | 40 | 2.280 |
Why?
|
| Percutaneous Coronary Intervention | 7 | 2024 | 160 | 2.050 |
Why?
|
| Vascular Calcification | 3 | 2019 | 25 | 1.820 |
Why?
|
| Heart Valve Prosthesis Implantation | 5 | 2019 | 153 | 1.730 |
Why?
|
| Coronary Angiography | 7 | 2021 | 178 | 1.710 |
Why?
|
| Coronary Stenosis | 4 | 2017 | 30 | 1.580 |
Why?
|
| Prosthesis Design | 7 | 2024 | 212 | 1.560 |
Why?
|
| Tricuspid Valve | 3 | 2017 | 22 | 1.550 |
Why?
|
| Heart Arrest | 4 | 2023 | 161 | 1.490 |
Why?
|
| Coronary Occlusion | 2 | 2021 | 6 | 1.290 |
Why?
|
| Balloon Valvuloplasty | 3 | 2024 | 10 | 1.240 |
Why?
|
| Atherectomy, Coronary | 2 | 2019 | 13 | 1.210 |
Why?
|
| Thromboxane B2 | 4 | 2022 | 17 | 1.160 |
Why?
|
| Coronary Artery Disease | 4 | 2019 | 277 | 1.160 |
Why?
|
| Coronary Artery Bypass | 3 | 2021 | 280 | 1.090 |
Why?
|
| Aged, 80 and over | 19 | 2024 | 5150 | 1.050 |
Why?
|
| Fractional Flow Reserve, Myocardial | 3 | 2016 | 13 | 1.030 |
Why?
|
| Tricuspid Valve Stenosis | 2 | 2017 | 3 | 1.020 |
Why?
|
| Treatment Outcome | 18 | 2024 | 5334 | 0.920 |
Why?
|
| Heart Transplantation | 2 | 2017 | 164 | 0.910 |
Why?
|
| Prosthesis Failure | 3 | 2024 | 71 | 0.890 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2023 | 85 | 0.880 |
Why?
|
| Myocardial Infarction | 5 | 2022 | 864 | 0.840 |
Why?
|
| Acute Coronary Syndrome | 3 | 2021 | 250 | 0.830 |
Why?
|
| Stents | 4 | 2021 | 468 | 0.830 |
Why?
|
| Risk Factors | 17 | 2024 | 5011 | 0.810 |
Why?
|
| Hemodynamics | 4 | 2024 | 231 | 0.790 |
Why?
|
| Defibrillators, Implantable | 2 | 2017 | 259 | 0.770 |
Why?
|
| Cardiac Catheterization | 3 | 2020 | 254 | 0.770 |
Why?
|
| Humans | 49 | 2024 | 59744 | 0.770 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2021 | 211 | 0.770 |
Why?
|
| Aged | 24 | 2024 | 13513 | 0.760 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 1 | 2021 | 30 | 0.740 |
Why?
|
| Myocardial Revascularization | 2 | 2020 | 72 | 0.720 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2021 | 46 | 0.710 |
Why?
|
| Aspirin | 2 | 2022 | 167 | 0.700 |
Why?
|
| Drug-Eluting Stents | 1 | 2021 | 53 | 0.680 |
Why?
|
| Tomography, Optical Coherence | 2 | 2019 | 214 | 0.670 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2021 | 167 | 0.660 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2019 | 16 | 0.650 |
Why?
|
| Male | 27 | 2024 | 27952 | 0.630 |
Why?
|
| Female | 28 | 2024 | 30926 | 0.630 |
Why?
|
| Graft Occlusion, Vascular | 2 | 2016 | 62 | 0.590 |
Why?
|
| Emergency Medical Services | 1 | 2021 | 260 | 0.580 |
Why?
|
| Cardiac Catheters | 1 | 2018 | 10 | 0.580 |
Why?
|
| Thromboxane A2 | 1 | 2017 | 5 | 0.570 |
Why?
|
| Equipment Safety | 1 | 2017 | 20 | 0.570 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2021 | 146 | 0.550 |
Why?
|
| Echocardiography | 5 | 2023 | 466 | 0.550 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2017 | 18 | 0.550 |
Why?
|
| Pacemaker, Artificial | 1 | 2017 | 44 | 0.550 |
Why?
|
| Middle Aged | 16 | 2024 | 16452 | 0.530 |
Why?
|
| Saphenous Vein | 2 | 2016 | 51 | 0.520 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 38 | 0.510 |
Why?
|
| Information Storage and Retrieval | 1 | 2016 | 60 | 0.500 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2015 | 35 | 0.470 |
Why?
|
| Ventricular Function, Left | 3 | 2022 | 258 | 0.440 |
Why?
|
| Heart Failure | 3 | 2022 | 858 | 0.420 |
Why?
|
| Electrocardiography | 4 | 2020 | 524 | 0.420 |
Why?
|
| Arterial Pressure | 1 | 2012 | 22 | 0.400 |
Why?
|
| Coronary Circulation | 1 | 2012 | 50 | 0.400 |
Why?
|
| Thromboembolism | 1 | 2013 | 70 | 0.400 |
Why?
|
| United States | 11 | 2024 | 7448 | 0.390 |
Why?
|
| Time Factors | 9 | 2024 | 3629 | 0.390 |
Why?
|
| Heparin | 1 | 2013 | 111 | 0.380 |
Why?
|
| Registries | 5 | 2024 | 805 | 0.380 |
Why?
|
| Heart Rate | 1 | 2013 | 309 | 0.370 |
Why?
|
| Recovery of Function | 3 | 2024 | 271 | 0.360 |
Why?
|
| Echocardiography, Three-Dimensional | 2 | 2023 | 41 | 0.340 |
Why?
|
| Acute Kidney Injury | 2 | 2022 | 133 | 0.330 |
Why?
|
| Multidetector Computed Tomography | 2 | 2020 | 20 | 0.310 |
Why?
|
| Stroke Volume | 3 | 2022 | 315 | 0.310 |
Why?
|
| Anticoagulants | 1 | 2013 | 480 | 0.310 |
Why?
|
| Hospitals | 2 | 2021 | 380 | 0.300 |
Why?
|
| Echocardiography, Doppler | 2 | 2019 | 133 | 0.290 |
Why?
|
| Heart Valve Diseases | 2 | 2018 | 90 | 0.270 |
Why?
|
| Equipment Design | 2 | 2017 | 334 | 0.260 |
Why?
|
| Reoperation | 2 | 2018 | 275 | 0.260 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 909 | 0.250 |
Why?
|
| Disease Management | 2 | 2017 | 220 | 0.240 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 2354 | 0.240 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 1541 | 0.240 |
Why?
|
| Retrospective Studies | 10 | 2024 | 6156 | 0.240 |
Why?
|
| Risk Assessment | 4 | 2024 | 1935 | 0.230 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 1489 | 0.230 |
Why?
|
| Foreign-Body Migration | 1 | 2024 | 20 | 0.220 |
Why?
|
| Emergency Service, Hospital | 2 | 2021 | 1024 | 0.210 |
Why?
|
| Heart Ventricles | 3 | 2023 | 255 | 0.210 |
Why?
|
| Biomarkers | 3 | 2020 | 1315 | 0.210 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2024 | 73 | 0.200 |
Why?
|
| Mitral Valve Prolapse | 1 | 2021 | 11 | 0.190 |
Why?
|
| Obstetric Labor Complications | 1 | 2021 | 24 | 0.180 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2021 | 31 | 0.180 |
Why?
|
| Shock, Cardiogenic | 2 | 2019 | 87 | 0.180 |
Why?
|
| Prasugrel Hydrochloride | 1 | 2021 | 12 | 0.180 |
Why?
|
| Fluoroscopy | 1 | 2021 | 62 | 0.180 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2021 | 13 | 0.180 |
Why?
|
| Postoperative Complications | 4 | 2024 | 1217 | 0.180 |
Why?
|
| Dissection | 1 | 2021 | 45 | 0.180 |
Why?
|
| Vascular Diseases | 1 | 2021 | 75 | 0.170 |
Why?
|
| Cause of Death | 2 | 2018 | 210 | 0.170 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 674 | 0.170 |
Why?
|
| Computed Tomography Angiography | 1 | 2020 | 113 | 0.160 |
Why?
|
| Patient Readmission | 2 | 2021 | 421 | 0.160 |
Why?
|
| Hemorrhage | 1 | 2021 | 259 | 0.160 |
Why?
|
| Atrial Pressure | 1 | 2019 | 4 | 0.160 |
Why?
|
| Ventricular Pressure | 1 | 2019 | 30 | 0.160 |
Why?
|
| Heart Valves | 1 | 2018 | 24 | 0.150 |
Why?
|
| Adult | 5 | 2021 | 15771 | 0.150 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2018 | 18 | 0.150 |
Why?
|
| Cohort Studies | 2 | 2023 | 2387 | 0.150 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 150 | 0.150 |
Why?
|
| Ventricular Remodeling | 1 | 2018 | 80 | 0.150 |
Why?
|
| Electromagnetic Phenomena | 1 | 2017 | 3 | 0.140 |
Why?
|
| Electrocoagulation | 1 | 2017 | 12 | 0.140 |
Why?
|
| Defibrillators | 1 | 2017 | 16 | 0.140 |
Why?
|
| Urinalysis | 1 | 2017 | 30 | 0.140 |
Why?
|
| Patient Discharge | 1 | 2021 | 493 | 0.140 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2018 | 77 | 0.140 |
Why?
|
| Thoracic Surgery | 1 | 2018 | 68 | 0.140 |
Why?
|
| Anesthesia, Conduction | 1 | 2017 | 11 | 0.140 |
Why?
|
| Mitral Valve | 1 | 2018 | 108 | 0.140 |
Why?
|
| Equipment Failure | 1 | 2017 | 65 | 0.140 |
Why?
|
| Subclavian Artery | 1 | 2017 | 26 | 0.140 |
Why?
|
| Length of Stay | 1 | 2021 | 790 | 0.140 |
Why?
|
| Feasibility Studies | 1 | 2019 | 531 | 0.140 |
Why?
|
| United States Food and Drug Administration | 1 | 2017 | 85 | 0.140 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 1038 | 0.140 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2017 | 12 | 0.140 |
Why?
|
| Aorta, Thoracic | 1 | 2017 | 81 | 0.140 |
Why?
|
| Patient Selection | 1 | 2019 | 467 | 0.130 |
Why?
|
| Electric Countershock | 1 | 2017 | 100 | 0.130 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2017 | 98 | 0.130 |
Why?
|
| Hospital Mortality | 1 | 2021 | 850 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 402 | 0.130 |
Why?
|
| Societies, Medical | 1 | 2018 | 339 | 0.130 |
Why?
|
| American Heart Association | 1 | 2017 | 122 | 0.130 |
Why?
|
| Dinoprost | 1 | 2016 | 19 | 0.130 |
Why?
|
| Semantics | 1 | 2016 | 57 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 679 | 0.120 |
Why?
|
| Vascular Patency | 1 | 2016 | 138 | 0.120 |
Why?
|
| Pandemics | 1 | 2020 | 618 | 0.120 |
Why?
|
| Prognosis | 2 | 2020 | 1613 | 0.120 |
Why?
|
| Cardiology | 1 | 2017 | 163 | 0.120 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 791 | 0.120 |
Why?
|
| Oxidative Stress | 1 | 2016 | 278 | 0.110 |
Why?
|
| Cells, Cultured | 2 | 2016 | 2095 | 0.110 |
Why?
|
| Infarction, Posterior Cerebral Artery | 1 | 2013 | 7 | 0.110 |
Why?
|
| Medicare | 1 | 2018 | 601 | 0.110 |
Why?
|
| Temporal Lobe | 1 | 2013 | 46 | 0.110 |
Why?
|
| Vertebrobasilar Insufficiency | 1 | 2013 | 23 | 0.110 |
Why?
|
| Long QT Syndrome | 1 | 2013 | 30 | 0.110 |
Why?
|
| Acute Disease | 1 | 2015 | 660 | 0.110 |
Why?
|
| Cerebral Infarction | 1 | 2013 | 77 | 0.100 |
Why?
|
| Prevalence | 3 | 2024 | 1262 | 0.100 |
Why?
|
| Stroke | 2 | 2021 | 1134 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 707 | 0.100 |
Why?
|
| Thromboxanes | 2 | 2022 | 9 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 440 | 0.100 |
Why?
|
| Comorbidity | 1 | 2015 | 1083 | 0.090 |
Why?
|
| Jugular Veins | 1 | 2011 | 29 | 0.090 |
Why?
|
| Hospitalization | 3 | 2024 | 1300 | 0.090 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2011 | 26 | 0.090 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2011 | 53 | 0.090 |
Why?
|
| Venous Thrombosis | 1 | 2011 | 111 | 0.080 |
Why?
|
| Endothelial Cells | 1 | 2011 | 174 | 0.080 |
Why?
|
| Antibodies, Neutralizing | 1 | 2011 | 179 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 2065 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2021 | 749 | 0.070 |
Why?
|
| Survival Rate | 2 | 2018 | 804 | 0.060 |
Why?
|
| Incidence | 2 | 2018 | 1245 | 0.060 |
Why?
|
| Pericardium | 1 | 2023 | 35 | 0.050 |
Why?
|
| Heart Atria | 1 | 2023 | 137 | 0.050 |
Why?
|
| Creatinine | 1 | 2022 | 130 | 0.050 |
Why?
|
| Inpatients | 1 | 2024 | 292 | 0.050 |
Why?
|
| Troponin | 1 | 2020 | 36 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2023 | 435 | 0.040 |
Why?
|
| Critical Care | 1 | 2023 | 402 | 0.040 |
Why?
|
| Diastole | 1 | 2019 | 90 | 0.040 |
Why?
|
| Logistic Models | 1 | 2021 | 1240 | 0.040 |
Why?
|
| Prosthesis Fitting | 1 | 2017 | 7 | 0.040 |
Why?
|
| Intraoperative Period | 1 | 2017 | 33 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2017 | 66 | 0.030 |
Why?
|
| Recurrence | 1 | 2018 | 608 | 0.030 |
Why?
|
| Europe | 1 | 2017 | 182 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 409 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 818 | 0.030 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2018 | 302 | 0.030 |
Why?
|
| Pregnancy | 1 | 2021 | 2226 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 1570 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 403 | 0.020 |
Why?
|
| Paracrine Communication | 1 | 2011 | 15 | 0.020 |
Why?
|
| Thrombomodulin | 1 | 2011 | 16 | 0.020 |
Why?
|
| Protein C | 1 | 2011 | 29 | 0.020 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2011 | 47 | 0.020 |
Why?
|
| Carotid Arteries | 1 | 2011 | 62 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2011 | 110 | 0.020 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2011 | 58 | 0.020 |
Why?
|
| Rabbits | 1 | 2011 | 326 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2011 | 1472 | 0.020 |
Why?
|
| Animals | 1 | 2011 | 19705 | 0.010 |
Why?
|